Bristol Discontinues Development Of Inhibitex Nuc, Will Take $1.8 Billion Hit
This article was originally published in The Pink Sheet Daily
On Aug. 1, Bristol halted Phase II study of nucleoside polymerase inhibitor BMS-986094 due to a serious case of cardiac toxicity – the pharma since has revealed that the afflicted patient died and nine total have been hospitalized with heart and kidney problems.
You may also be interested in...
While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.